FiercePharmaAsia—Taiho, Otsuka, Chugai KRAS deals; Biocon biologics spinoff; Mark Alles' new title

10th January 2020 Uncategorised 0

A group of Japanese drugmakers have found licensees for their KRAS-focused projects. Biocon secured a private equity investment for its biologics business in preparation for an IPO. Ex-Celgene chief Mark Alles re-emerged as a board director at Chinese biotech Antengene. And more.

More: FiercePharmaAsia—Taiho, Otsuka, Chugai KRAS deals; Biocon biologics spinoff; Mark Alles' new title
Source: fierce